Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.50) by 8 percent. This is a 6.98 percent decrease over losses of $(0.43) per share from the same period last year.